6580.TWO TaiRx, Inc.
- Market cap
- TWD 1.24B
- P/E
- -
- P/B
- 3.61x
- ROE
- -50.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6580.TWO undervalued?
Graham numberThe Graham number of TaiRx, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TaiRx, Inc. fundamental analysis
No fundamental analysis for TaiRx, Inc. yet.
TaiRx, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TaiRx, Inc.
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of sele…
Full company profileTaiRx, Inc. financial statements
TaiRx, Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 3.16M | 3.36M | 5.14M | 6.92M | 5.08M | 8.22M | 27.9M |
| Gross Profit | 1.50M | 1.60M | 2.45M | 3.95M | 2.44M | 1.34M | 10.1M |
| Operating Income | -163M | -163M | -130M | -213M | -215M | -146M | -237M |
| EBITDA | -216M | -158M | -123M | -207M | -209M | -131M | -214M |
| Net Income | -218M | -159M | -126M | -212M | -212M | -139M | -221M |
| EPS | -3.60 | -2.37 | -1.38 | -2.37 | -2.31 | -1.26 | -1.97 |
| Balance Sheet | |||||||
| Total Assets | 489M | 837M | 707M | 534M | 834M | 685M | 465M |
| Total Liabilities | 31.8M | 39.4M | 30.8M | 54.9M | 60.6M | 36.3M | 23.6M |
| Shareholders' Equity | 451M | 789M | 675M | 478M | 772M | 647M | 442M |
| Cash & Short-term Investments | 326M | 674M | 545M | 358M | 660M | 514M | 136M |
| Total Debt | 8.76M | 5.60M | 2.42M | 15.5M | 12.3M | 10.4M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -169M | -142M | -124M | -186M | -195M | -150M | -178M |
| Capital Expenditure | 0.00 | 401K | 946K | 317K | 313K | 321K | 1.15M |
| Free Cash Flow | -169M | -142M | -125M | -186M | -195M | -150M | -180M |
| Ratios | |||||||
| ROE | -48.3% | -20.2% | -18.6% | -44.3% | -27.5% | -21.5% | -50.1% |
| ROA | -44.5% | -19.0% | -17.8% | -39.6% | -25.5% | -20.3% | -47.5% |
| Net Profit Margin | -6,900.0% | -4,745.0% | -2,443.4% | -3,056.1% | -4,177.3% | -1,688.6% | -793.3% |
| Debt to Equity | 0.02x | 0.01x | 0.00x | 0.03x | 0.02x | 0.02x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
TaiRx, Inc. dividends
TaiRx, Inc. has not paid dividends in the last 7 fiscal years.
Last stock split: 850:1000 on Nov 14, 2019.
Who owns TaiRx, Inc.
Ownership data of TaiRx, Inc. is not available yet.
TaiRx, Inc. company profile
- Company name
- TaiRx, Inc.
- Ticker
- 6580.TWO
- ISIN
- TW0006580004
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 66, San-Chung Road, Taipei, Taiwan, 115602
- Phone
- 886 2 2653 5007
- Website
- trx.com.tw
About TaiRx, Inc.
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs for the use in cancer therapy. TaiRx, Inc. was founded in 2011 and is based in Taipei, Taiwan.
TaiRx, Inc. management
4- Dr. Du-Shieng Chien Ph.D.Co-Founder, President, CEO & Director
- Dr. Yi-Wen Chu Ph.D.Senior VP & Director
- Mr. Huang Shiqi M.A.CFO & Accounting Supervisor
- Mr. Yu-Tung Hung M.Sc.Chief Product Officer, Pharmaceutical & Health Products